0 CHECKOUT

Nicotine Addiction - Pipeline Review, H2 2015

  • ID: 3502766
  • October 2015
  • 63 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Astraea Therapeutics, LLC
  • Cerecor Inc.
  • Omeros Corporation
  • RTI International
  • MORE

Nicotine Addiction - Pipeline Review, H2 2015

Summary

The report ‘Nicotine Addiction - Pipeline Review, H2 2015’, provides an overview of the Nicotine Addiction’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nicotine Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nicotine Addiction and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Astraea Therapeutics, LLC
  • Cerecor Inc.
  • Omeros Corporation
  • RTI International
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Nicotine Addiction Overview

Therapeutics Development

Pipeline Products for Nicotine Addiction - Overview

Pipeline Products for Nicotine Addiction - Comparative Analysis

Nicotine Addiction - Therapeutics under Development by Companies

Nicotine Addiction - Therapeutics under Investigation by Universities/Institutes

Nicotine Addiction - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Nicotine Addiction - Products under Development by Companies

Nicotine Addiction - Products under Investigation by Universities/Institutes

Nicotine Addiction - Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Astraea Therapeutics, LLC

Cerecor Inc.

Embera NeuroTherapeutics, Inc.

FORUM Pharmaceuticals Inc.

Heptares Therapeutics Limited

Omeros Corporation

RTI International

Nicotine Addiction - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(oxazepam + metyrapone) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ADX-71441 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AT-1001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CERC-501 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drugs to Inhibit FAAH for CNS Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

encenicline hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

EROA-101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

OMS-405 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

OMS-527 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Antagonize Alpha-4 Beta-2 Nicotinic Acetylcholine Receptor for CNS Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Antagonize Orexin 1 for Binge Eating Disorder and Nicotine Addiction - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Vaccine for Nicotine Addiction - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Vaccine for Nicotine Addiction - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Nicotine Addiction - Recent Pipeline Updates

Nicotine Addiction - Dormant Projects

Nicotine Addiction - Discontinued Products

Nicotine Addiction - Product Development Milestones

Featured News & Press Releases

Jul 10, 2014: Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction

Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction

May 05, 2011: Omeros Announces Expansion Of Potential Indications For PDE7 Inhibitors

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Nicotine Addiction, H2 2015

Number of Products under Development for Nicotine Addiction - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015

Nicotine Addiction - Pipeline by Addex Therapeutics Ltd, H2 2015

Nicotine Addiction - Pipeline by Astraea Therapeutics, LLC, H2 2015

Nicotine Addiction - Pipeline by Cerecor Inc., H2 2015

Nicotine Addiction - Pipeline by Embera NeuroTherapeutics, Inc., H2 2015

Nicotine Addiction - Pipeline by FORUM Pharmaceuticals Inc., H2 2015

Nicotine Addiction - Pipeline by Heptares Therapeutics Limited, H2 2015

Nicotine Addiction - Pipeline by Omeros Corporation, H2 2015

Nicotine Addiction - Pipeline by RTI International, H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Nicotine Addiction Therapeutics - Recent Pipeline Updates, H2 2015

Nicotine Addiction - Dormant Projects, H2 2015

Nicotine Addiction - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Nicotine Addiction, H2 2015

Number of Products under Development for Nicotine Addiction - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Addex Therapeutics Ltd
Astraea Therapeutics, LLC
Cerecor Inc.
Embera NeuroTherapeutics, Inc.
FORUM Pharmaceuticals Inc.
Heptares Therapeutics Limited
Omeros Corporation
RTI International

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Amneal Pharmaceuticals LLC.
  • Amgen Inc.
  • LEO Laboratories Ltd.
  • Pfizer Inc.
  • Roche Diagnostics Ltd.
  • Merck & Co., Inc.
  • Sanofi S.A.